Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate
Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec"). The agreement gives Eurocine Vaccines the exclusive global rights to develop, manufacture and commercialize vaccine candidates against Herpes Simplex Virus Type 2, HSV-2, based on the technologies developed by Redbiotec.The agreement covers both an mRNA and a protein-based technology, its documentation and patents within the field of HSV-2. By entering this agreement, all activities related to the development, manufacture and